How were new medicines discovered?
The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Items 401–500 of 1,000
Geerts, H., Wikswo, J. P., van der Graaf, P. H., Bai, J. P. F., Gaiteri, C., Bennett, D. A., Swalley, S. E., Schuck, E. L., Kaddurah‐Daouk, R., Tsaioun, K., et al. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12478 · Cited by 56
On the Role of Artificial Intelligence in Genomics to Enhance Precision Medicine
Álvarez-Machancoses, Ó., deAndrés‐Galiana, E. J., Cernea, A., de la Viña, J. F. S., & Fernández‐Martínez, J. L. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s205082 · Cited by 60
Targeting RNA structures in diseases with small molecules
Shao, Y., & Zhang, Q. C. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200011 · Cited by 54
Foley, T. L., Burchett, W., Chen, Q., Flanagan, M. E., Kapinos, B., Li, X.-Y., Montgomery, J. I., Ratnayake, A. S., Zhu, H., & Peakman, M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220979589 · Cited by 52
Insect Acetylcholinesterase as a Target for Effective and Environmentally Safe Insecticides
Pang, Y. (2014) · Advances in insect physiology · doi:10.1016/b978-0-12-417010-0.00006-9 · Cited by 55
CETSA: A Target Engagement Assay with Potential to Transform Drug Discovery
Jensen, A. J., Molina, D. M., & Lundbäck, T. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.50 · Cited by 49
The resurgence of phenotypic screening in drug discovery and development
Wagner, B. K. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1122589 · Cited by 53
Moree, B., Yin, G., Lázaro, D. F., Munari, F., Strohäker, T., Giller, K., Becker, S., Outeiro, T. F., Zweckstetter, M., & Salafsky, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.636027 · Cited by 49
Merkert, S., Schubert, M., Olmer, R., Engels, L., Radetzki, S., Veltman, M., Scholte, B. J., Zöllner, J., Pedemonte, N., Galietta, L. J. V., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.04.014 · Cited by 51
Renner, H., Schöler, H. R., & Bruder, J. M. (2021) · Movement Disorders · doi:10.1002/mds.28775 · Cited by 49
Peng, X., Zhang, S., Wang, Y., Zhou, Z., Yu, Z., Zhong, Z., Zhang, L., Chen, Z., Claret, F. X., Elkabets, M., et al. (2022) · Advanced Science · doi:10.1002/advs.202205529 · Cited by 62
Small Molecule Bromodomain Inhibitors
Chung, C. (2012) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-396493-9.00001-7 · Cited by 50
Bilican, B., Livesey, M. R., Haghi, G., Qiu, J., Burr, K., Siller, R., Hardingham, G. E., Wyllie, D. J. A., & Chandran, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085932 · Cited by 48
Building Predictive Models for Mechanism-of-Action Classification from Phenotypic Assay Data Sets
Berg, E. L., Yang, J., & Polokoff, M. A. (2013) · SLAS Discovery · doi:10.1177/1087057113505324 · Cited by 47
Guo, Y., Partch, C. L., Key, J., Card, P. B., Pashkov, V., Patel, A., Bruick, R. K., Wurdak, H., & Gardner, K. H. (2013) · ACS Chemical Biology · doi:10.1021/cb300604u · Cited by 47
Personalized Cardiovascular Medicine and Drug Development
Loscalzo, J. (2012) · Circulation · doi:10.1161/circulationaha.111.089243 · Cited by 49
Singh, R. K., Najmi, A. K., & Dastidar, S. G. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.03.023 · Cited by 50
Opportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research
Brown, D. G., & Wobst, H. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00797 · Cited by 48
Shanshak, M., Budagumpi, S., Małecki, J. G., & Keri, R. S. (2020) · Applied Organometallic Chemistry · doi:10.1002/aoc.5544 · Cited by 49
The iPPI-DB initiative: a community-centered database of protein–protein interaction modulators
Torchet, R., Druart, K., Ruano, L. C., Moine-Franel, A., Borges, H., Doppelt‐Azeroual, O., Brancotte, B., Mareuil, F., Nilges, M., Ménager, H., et al. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa1091 · Cited by 52
JTE-607, a multiple cytokine production inhibitor, targets CPSF3 and inhibits pre-mRNA processing
Kakegawa, J., Sakane, N., Suzuki, K., & Yoshida, T. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.004 · Cited by 48
Gul, S., & Hadian, K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.954544 · Cited by 54
Predictive methods in drug repurposing: gold mine or just a bigger haystack?
Cavalla, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.12.009 · Cited by 52
Combating neurodegenerative disease with chemical probes and model systems
Narayan, P. S., Ehsani, S., & Lindquist, S. L. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1663 · Cited by 60
Next-Generation Phenotypic Screening
Warchal, S. J., Unciti-Broceta, A., & Carragher, N. O. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0025 · Cited by 43
Li, J., Ma, J., Meng, G., Lin, H., Wu, S. L. Y., Wang, J., Luo, J., Xu, X., Tough, D. F., Lindon, M. J., et al. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.07.006 · Cited by 49
Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease
Milenkovic, U., Ilg, M. M., Cellek, S., & Albersen, M. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2019.02.004 · Cited by 46
Core-shell hydrogel beads with extracellular matrix for tumor spheroid formation
Yu, L., Grist, S. M., Nasseri, S. S., Cheng, E., Hwang, Y.-C. E., Ni, C., & Cheung, K. C. (2015) · Biomicrofluidics · doi:10.1063/1.4918754 · Cited by 55
The mouse as a model for neuropsychiatric drug development
Howe, J. R., Bear, M. F., Golshani, P., Klann, E., Lipton, S. A., Mucke, L., Şahin, M., & Silva, A. J. (2018) · Current Biology · doi:10.1016/j.cub.2018.07.046 · Cited by 52
David, F., Davis, A. M., Gossing, M., Hayes, M. A., Romero, E., Scott, L. H., & Wigglesworth, M. J. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211000669 · Cited by 50
Oishi, H., Tabibzadeh, N., & Morizane, R. (2024) · Biofabrication · doi:10.1088/1758-5090/ad38df · Cited by 50
The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review
Fowler, C. J. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_4 · Cited by 46
Jochmans, D., Leyssen, P., & Neyts, J. H. (2012) · Journal of Virological Methods · doi:10.1016/j.jviromet.2012.04.011 · Cited by 45
Overcoming the Challenges of Drug Discovery for Neglected Tropical Diseases: The A·WOL Experience
Johnston, K. L., Ford, L., & Taylor, M. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113511270 · Cited by 45
Identifizierung der Zielproteine bioaktiver Verbindungen: Die Suche nach der Nadel im Heuhaufen
Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013) · Angewandte Chemie · doi:10.1002/ange.201208749 · Cited by 46
The power of combining phenotypic and target-focused drug discovery
Heilker, R., Lessel, U. F., & Bischoff, D. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.10.009 · Cited by 49
Lecca, D., Bader, M., Tweedie, D., Hoffman, A. F., Jung, Y. J., Hsueh, S., Hoffer, B. J., Becker, R. E., Pick, C. G., Lupica, C. R., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104528 · Cited by 48
The Resurrection of Phenotypic Drug Discovery
Childers, W. E., Elokely, K. M., & Abou-Gharbia, M. A. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00006 · Cited by 48
Kudo, K., Hashimoto, T., Hashimoto, J., Kozone, I., Kagaya, N., Ueoka, R., Nishimura, T., Komatsu, M., Suenaga, H., Ikeda, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17769-2 · Cited by 46
Constellation Pharmacology: A New Paradigm for Drug Discovery
Teichert, R. W., Schmidt, E. W., & Olivera, B. M. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124551 · Cited by 45
Network Pharmacology for Cancer Drug Discovery: Are We There Yet?
Azmi, A. S. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.44 · Cited by 45
Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts
Sturtzel, C., Grissenberger, S., Bozatzi, P., Scheuringer, E., Wenninger-Weinzierl, A., Zajec, Z., Dernovšek, J., Pascoal, S., Gehl, V., Kutsch, A., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00386-9 · Cited by 45
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 46
Vauquelin, G. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1067196 · Cited by 49
Small Molecule Screening in Human Induced Pluripotent Stem Cell-derived Terminal Cell Types
Engle, S. J., & Vincent, F. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.529156 · Cited by 56
Composition and applications of focus libraries to phenotypic assays
Wassermann, A. M., Camargo, L. M., & Auld, D. S. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00164 · Cited by 42
Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development
Duran‐Frigola, M., Mosca, R., & Aloy, P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.004 · Cited by 51
Wassermann, A. M., Lounkine, E., Urban, L., Whitebread, S., Chen, S., Hughes, K., Guo, H., Kutlina, E., Fekete, A., Klumpp, M., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb5001839 · Cited by 43
Keiser, J., Panić, G., Adelfio, R., Cowan, N., Vargas, M., & Scandale, I. (2016) · Parasites & Vectors · doi:10.1186/s13071-016-1616-0 · Cited by 50
Echeazarra, L., Hortigon-Vinagre, M. P., Casis, Ó., & Gallego, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.607860 · Cited by 49
Strategies in the Search for New Lead Compounds or Original Working Hypotheses
Wermuth, C. G., Villoutreix, B. O., Grisoni, S., Olivier, A., & Rocher, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00004-3 · Cited by 55
Biosynthetic medicinal chemistry of natural product drugs
Koehn, F. E. (2012) · MedChemComm · doi:10.1039/c2md00316c · Cited by 48
Induced Pluripotent Stem Cells for the Study of Cardiovascular Disease
Savla, J. J., Nelson, B., Perry, C. N., & ADLER, E. D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.038 · Cited by 48
Satyanarayanajois, S. D., & Hill, R. A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.135 · Cited by 49
Target identification by image analysis
Fetz, V., Prochnow, H., Brönstrup, M., & Sasse, F. (2016) · Natural Product Reports · doi:10.1039/c5np00113g · Cited by 43
Huang, R., Bonnichon, A., Claridge, T. D. W., & Leung, I. K. H. (2017) · Scientific Reports · doi:10.1038/srep43727 · Cited by 56
Natural and Synthetic Flavonoids as Potent Mycobacterium tuberculosis UGM Inhibitors
Villaume, S. A., Fu, J. H., N’Go, I., Liang, H., Lou, H., Kremer, L., Pan, W., & Vincent, S. P. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701812 · Cited by 46
APOL1 Nephropathy: A Population Genetics and Evolutionary Medicine Detective Story
Kruzel-Davila, E., Wasser, W. G., & Skorecki, K. L. (2017) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2017.07.002 · Cited by 44
Predictive models for estimating cytotoxicity on the basis of chemical structures
Sun, H., Wang, Y., Cheff, D. M., Hall, M. D., & Shen, M. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115422 · Cited by 43
The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development
Ayuso, M., Buyssens, L. A., Stroe, M., Valenzuela, A., Allegaert, K., Smits, A., Annaert, P., Mulder, A., Carpentier, S., Ginneken, C. J. V., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010044 · Cited by 47
Systems biology, complexity, and the impact on antiepileptic drug discovery
Margineanu, D. G. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.08.029 · Cited by 45
Metabolic Disease Drug Discovery— “Hitting the Target” Is Easier Said Than Done
Moller, D. E. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.012 · Cited by 47
Boussaad, I., Cruciani, G., Bolognin, S., Antony, P., Dording, C. M., Kwon, Y.-J., Heutink, P., Fava, E., Schwamborn, J. C., & Krüger, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-81129-3 · Cited by 42
Gaetani, M., & Zubarev, R. A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2624-5_7 · Cited by 47
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
Dahlin, J. L., Hua, B. K., Zucconi, B. E., Nelson, S. D., Singh, S., Carpenter, A. E., Shrimp, J. H., Lima‐Fernandes, E., Wawer, M. J., Chung, L. P. W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36829-x · Cited by 49
Brundin, P., Barker, R. A., Conn, P. J., Dawson, T. M., Kieburtz, K. D., Lees, A. J., Schwarzschild, M. A., Tanner, C. M., Isaacs, T., Duffen, J., et al. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-139000 · Cited by 43
Lim, M. A., Louie, B., Ford, D., Heath, K. M., Cha, P., Betts-LaCroix, J., Lum, P. Y., Robertson, T. L., & Schaevitz, L. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00818 · Cited by 47
Nan, J.-X., Yang, J., Lin, H., Yan, Y.-C., Zhou, S.-M., Wei, X.-F., Chen, Q., Yang, W., Qu, R., & Yang, G. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c07782 · Cited by 42
Druggability predictions: methods, limitations, and applications
Barril, X. (2012) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1134 · Cited by 46
Metzger, J. J., Serras, C. P., Adhikari, A. S., Haremaki, T., Galgoczi, S., Siggia, E. D., Brivanlou, A. H., & Etoc, F. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100297 · Cited by 53
Yin, N., Pei, J., & Lai, L. (2013) · Molecular BioSystems · doi:10.1039/c3mb25471b · Cited by 42
Reisen, F., Zhang, X., Gabriel, D., & Selzer, P. (2013) · SLAS Discovery · doi:10.1177/1087057113501390 · Cited by 41
A new paradigm for navigating compound property related drug attrition
Barton, P., & Riley, R. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.010 · Cited by 48
McGown, A., Shaw, P. J., & Ramesh, T. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0122-3 · Cited by 41
Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors
Conway, J. R. W., Warren, S. C., & Timpson, P. (2017) · Methods · doi:10.1016/j.ymeth.2017.04.014 · Cited by 42
Screening and identification of novel biologically active natural compounds
Newman, D. J. (2017) · F1000Research · doi:10.12688/f1000research.11221.1 · Cited by 41
Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics
Norman, G. A. V. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.09.002 · Cited by 50
Ferrusquía‐Jiménez, N. I., Chandrakasan, G., Torres‐Pacheco, I., Rico-García, E., Feregrino‐Pérez, A. A., & Guevara-González, R. G. (2020) · Journal of Plant Growth Regulation · doi:10.1007/s00344-020-10129-w · Cited by 46
Rao, S. P. S., Manjunatha, U. H., Mikolajczak, S. A., Ashigbie, P. G., & Diagana, T. T. (2023) · Trends in Parasitology · doi:10.1016/j.pt.2023.01.010 · Cited by 44
Kumar, V., Lakshman, P. K. C., Prasad, T. K., Manjunath, K., Bairy, S. G., Vasu, A. S., Ganavi, B., Jasti, S., & Kamariah, N. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23864 · Cited by 50
Min, Y., Ye, W., Wang, P., Wang, X., Li, H., Wu, N., Bauer, S., Zheng, S., Shi, Y., Wang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202405404 · Cited by 54
Hayashi, Y., Suemitsu, E., Kajimoto, K., Sato, Y., Akhter, A., Sakurai, Y., Hatakeyama, H., Hyodo, M., Kaji, N., Baba, Y., et al. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.4 · Cited by 40
Protein-Directed Dynamic Combinatorial Chemistry: A Guide to Protein Ligand and Inhibitor Discovery
Huang, R., & Leung, I. K. H. (2016) · Molecules · doi:10.3390/molecules21070910 · Cited by 40
Meanwell, N. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00915 · Cited by 42
Label-free target identification in drug discovery via phenotypic screening
Park, H., Ha, J., & Park, S. B. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.006 · Cited by 42
Hakkim, F. L., Bakshi, H. A., Khan, S. S., Nasef, M., Farzand, R., Sam, S., Rashan, L. J., Al-Baloshi, M. S., Hasson, S. S., Jabri, A. A. A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26930 · Cited by 42
Al-Husseini, J. K., Stanton, N. J., Selassie, C. R. D., & Johal, M. S. (2019) · Langmuir · doi:10.1021/acs.langmuir.9b02318 · Cited by 40
Drug discovery in ophthalmology: past success, present challenges, and future opportunities
Gower, N. J. D., Barry, R. J., Edmunds, M. R., Titcomb, L. C., & Denniston, A. K. (2016) · BMC Ophthalmology · doi:10.1186/s12886-016-0188-2 · Cited by 41
Mullane, K., & Williams, M. J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.002 · Cited by 42
Pavan, F. R., Poelhsitz, G. V., Cunha, L. V. P. D., Barbosa, M. I. F., Leite, S. R. A., Batista, A. A., Cho, S., Franzblau, S. G., de Camargo, M. S., Resende, F. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064242 · Cited by 55
Chemical Interrogation of the Neuronal Kinome Using a Primary Cell-Based Screening Assay
Al‐Ali, H., Schürer, S. C., Lemmon, V., & Bixby, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb300584e · Cited by 41
Metabolically re-modeling the drug pipeline
Oberhardt, M., Yizhak, K., & Ruppin, E. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.05.006 · Cited by 43
Fox, C. S., Hall, J. L., Arnett, D. K., Ashley, E. A., Delles, C., Engler, M. B., Freeman, M. W., Johnson, J. A., Lanfear, D. E., Liggett, S. B., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000211 · Cited by 46
Kim, H., Tùng, T. T., & Park, S. B. (2013) · Organic Letters · doi:10.1021/ol402872b · Cited by 39
Andersson, T. B. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12804 · Cited by 39
Heparan Sulfate as a Therapeutic Target in Tauopathies: Insights From Zebrafish
Naini, S. M. A., & Soussi-Yanicostas, N. (2018) · Front. Cell Dev. Biol. · doi:10.3389/fcell.2018.00163 · Cited by 35
Li, Y., He, Y., Shao, T., Pei, H., Guo, W., Mi, D., Krimm, I., Zhang, Y., Wang, P., Wang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00059 · Cited by 39
Repurposing antimycotic ciclopirox olamine as a promising anti-ischemic stroke agent
Feng, H., Hu, L., Zhu, H., Tao, L.-X., Wu, L., Zhao, Q., Gao, Y., Gong, Q., Mao, F., Li, X., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.002 · Cited by 43
Ghaderzadeh, M., Shalchian, A., Irajian, G., Sadeghsalehi, H., Bialvaei, A. Z., & Sabet, B. (2024) · Iranian Journal of Medical Microbiology · doi:10.30699/ijmm.18.3.135 · Cited by 42
Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery
Ye, F. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.01.004 · Cited by 38
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.